Clinicians Should Consider Patient Concerns Amid Rise in Early-Onset Cancers

Commentary
Video

Clinicians should not dismiss the concerns of younger patients who suspect they may have breast cancer, especially amid an increase in early-onset disease according to Monique Gary, DO, MSc, FACS.

Although breast cancer has been historically recognized as a disease associated with aging, it is crucial to encourage younger populations of patients to stay vigilant of potential symptoms due to earl-onset incidence increasing over time, Monique Gary, DO, MSc, FACS, said during a conversation with CancerNetwork®.

In an interview concerning the findings from a study published in JAMA Network Open that highlighted a rise in early-onset breast cancer from 2010 to 2019, Gary, a breast surgeon and medical director at Grand View Health, emphasized the importance of listening to patient concerns and taking them seriously, as it could be a matter of life or death.

Transcript:

We should pay attention to the patient, and not just the patterns. Too often, young people are dismissed because they don’t fit the typical mold of what cancer looks like. We have historically been taught that cancer is largely a disease of aging. And while there are juvenile and pediatric cancers, historically, breast cancer hasn’t been one of them, [as well as] uterine cancer and colon cancer. Because we’re seeing younger and younger people develop these cancers, it means that we need to pay attention to those symptoms, [and] it means that we need to teach young people to pay attention to their bodies and not just power through without understanding the changes because they’re too young for screening. It’s not like you just have to wait for a colonoscopy. By the time you wait for that colonoscopy, you may have advanced disease or you could be dead.

You have to learn to listen to your body. We have to teach that we have to learn to listen to and believe our patients. Those are really great takeaways from this.

Reference

Koh B, Hao Tan DJ, Ng HN, et al. Patterns in cancer incidence among people younger than 50 years in the US, 2010 to 2019. JAMA Netw Open. 2023;6(8):e2328171. doi:10.1001/jamanetworkopen.2023.28171

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.